The top 10 drugs losing US exclusivity in 2022 BioNTech-Regeneron add 3rd tumor type to partnership testing cancer vaccines with Libtayo ViVE 2022: How UnitedHealth, Humana are thinking about 'techquity' On Medtronic's tail, Axonics scores FDA nod for 15-year neurostim implant for incontinence Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters ViVE 2022: Google Health expands AI capabilities of Care Studio to organize patient data GV-backed DNAnexus snags $200M to build out genomic data analytics platform Novartis eyes next-gen AAV gene therapies in $1.75B Voyager biobucks pact Sanofi deploying $1B to turn France into 'pioneer mRNA nation' Healthcare sector adds a hefty 63,500 jobs in February but still lags pre-pandemic employment Sherlock Biosciences unearths $80M to bring CRISPR-based tests into the home As Eli Lilly grows beyond Research Triangle Park, biopharmas big and small are tapping North Carolina's 'limitless' potential Featured Story | By Eric Sagonowsky,Kevin Dunleavy,Fraiser Kansteiner With AbbVie’s megablockbuster Humira set to face an onslaught of biosimilars next year, industry watchers have long circled 2023 as the year of the major pharma patent cliff. But this year’s slate of top losses of exclusivity covers a hefty slate of brands worth more than $17 billion in annual sales. read more |
| |
|---|
|
Top Stories By Max Bayer BioNTech wants to run it back with Regeneron, extending a partnership first announced in 2020 to combine a cancer vaccine with the approved treatment Libtayo in the clinic, this time for advanced non-small cell lung cancer. read more By Paige Minemyer MIAMI—Two key topics have dominated the industry conversation amid the COVID-19 pandemic: health equity and the role of technology. But these are not distinct entities, insurance executives said Monday at the inaugural ViVE Conference in Miami. read more By Andrea Park The race to treat a number of health conditions using neurostimulation technology is a marathon, not a sprint—and Medtronic and Axonics Modulation Technologies are aiming for a photo finish. read more By Eric Sagonowsky When Gilead Sciences picked up Immunomedics and the breast cancer drug Trodelvy for $21 billion a couple years back, the company billed the buyout as a major expansion into oncology. Now, the California-based drugmaker is laying off more than 100 staffers based out of the former Immunomedics headquarters as it gears up for change in New Jersey. read more By Heather Landi During the ViVE 2022 conference, Google Health executive Paul Muret detailed how Care Studio is using its tech expertise to unify patient data for clinicians. read more By Andrea Park So far, according to DNAnexus, the platform is used by seven of the world’s top 10 pharmaceutical companies and eight of the 10 biggest diagnostics developers—to single out just a few of its more than 12,000 total users located in four dozen countries across the globe. read more By Annalee Armstrong In Novartis’ perennial hunt for innovative therapies to bring under its wing, improving on gene therapy has always been kept top of mind. And the Swiss pharma continues to do just that thanks to a new biobucks deal with Voyager Therapeutics worth up to $1.75 billion. read more By Kyle LaHucik Sanofi will invest about $1 billion in its home country to beef up mRNA R&D and vaccines production in France. The move is part of the Big Pharma's broader $2.2 billion mRNA commitment revealed last summer. read more By Dave Muoio Healthcare employers saw their strongest jobs recovery in months, with ambulatory services, in particular, adding thousands of workers to their payrolls. read more By Conor Hale Since its 2019 launch, the former Fierce 15 winner has secured an FDA authorization for a COVID-19 test powered by the gene editing method. read more By Fraiser Kansteiner There are 775 or more life science companies in the state of North Carolina that directly employ about 68,000 people, Doug Edgeton, president and CEO of the North Carolina Biotechnology Center, said in an interview. read more |
